Ўзбекистон Республикаси Давлат фармакопеясини нашр (қайта нашр) этишга тайёрлаш

The press service of the SSV reports on the ongoing vaccination process in the country.

The Resolution of the Cabinet of Ministers of 03.08.2021 No. 486 "On Additional Measures to Implement the Requirements of Good Practices (GxP) in the Pharmaceutical Industry"

Announcement of a Competition for the procurement of services for the first edition of the first volume of the State Pharmacopoeia of the Republic of Uzbekistan in two parts (in two books in one box, in Russian and Uzbek in each).

Sanofi informs you about the new risk of developing regurgitation / heart valve failure associated with the use of fluoroquinolones for systemic and inhalation use.

Sanofi, in agreement with the Pharmacological Committee of the State Center for Expertise and Standardization of Medicines, Medical Devices and Medical Equipment, informs you of the following important data regarding the use of Plaquenil (hydroxychloroquine).

The main principles of combating corruption are: legality; priority of the rights, freedoms and legitimate interests of citizens; openness and transparency; consistency; interaction between the state and civil society; priority of measures to prevent corruption; inevitability of responsibility.

In connection with the announcement of the coronavirus pandemic (COVID-19) by the World Health Organization, today extensive work is being done to prevent the spread of this dangerous infection in the country.

Pursuant to the Decree of the President of the Republic of Uzbekistan dated 23.04.19 No. PP-4297, the SUE "DVTBTTESDM" informs all interested parties.

Information on the decision to suspend the Registration Certificate for products containing fenspiride.